Tafenoquine
From Wikipedia, the free encyclopedia
 |
|
|
Tafenoquine
|
|
| Systematic (IUPAC) name | |
| N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl) phenoxy]quinolin-8-yl]pentane-1,4-diamine |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C24H28F3N3O3 |
| Mol. mass | 463.493 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Tafenoquine (also called WR-238605 or SB-252263) is an 8-aminoquinoline drug manufactured by GlaxoSmithKline that is currently being investigated as a potential treatment for malaria, as well as for malaria prevention.[1][2]
The main advantage of tafenoquine is that it has a long half-life and therefore does not need to be taken as frequently as primaquine. Like primaquine, tafenoquine causes haemolysis in people with G-6-PD deficiency.[1]
The dose of tafenoquine has not been firmly established, but for the treatment of Plasmodium vivax malaria, a dose of 800 mg over three days has been used.[3]
[edit] References
- ^ a b Shanks GD, Oloo AJ, Aleman GM, et al. (2001). "A New Primaquine Analogue, Tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.". Clin Infect Dis 33: 1968–74.
- ^ Lell B, Faucher JF, Missinou MA, et al. (2000). "Malaria chemoprophylaxis with tafenoquine: a randomised study.". Lancet 355 (9220): 2041–5. PMID 10885356.
- ^ Nasvelda P, Kitchener S. (2005). "Treatment of acute vivax malaria with tafenoquine.". Trans R Soc Trop Med Hyg 99 (1): 2–5. DOI:10.1016/j.trstmh.2004.01.013.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
